Healthcare Policy
19 articles on Healthcare Policy, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
How Iconic Philly Food Brands Are Adapting to Calorie-Conscious Consumers
Philadelphia's iconic food brands are evolving, introducing high-protein and functional food options to cater to the growing number of calorie-conscious consumers, influenced by trends like GLP-1 medications and a desire for healthier choices.
8 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Ozempic, Mounjaro & More: Bridging the Global Gap for Cheaper Biologics
While generics have revolutionized drug affordability, newer biologics like those used for weight loss and diabetes face unique challenges. A new study reveals how varying international regulations are slowing the adoption of affordable biosimilars, impacting patient access and costs.
6 min read
GLP-1s for Weight Loss: The NHS Two-Year Limit & Private Costs
As GLP-1 agonists revolutionize weight management, many patients face a critical juncture when NHS funding ends. This article delves into the realities of these powerful medications, the challenges of long-term access, and the growing divide between publicly funded care and private treatment costs.
7 min read
Supreme Court Ruling: Medicare Drug Price Negotiations Move Forward
In a significant victory for healthcare cost containment, the Supreme Court has allowed Medicare to proceed with negotiating drug prices. This decision upholds a key provision of the Inflation Reduction Act and could impact the cost of many prescription medications, including widely used GLP-1 agonists.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.
2 min read
Boston Mayor Wu, Unions Limit GLP-1 Coverage for Weight Loss Drugs
Boston Mayor Michelle Wu announced a deal with unions to implement prior authorization for GLP-1 weight loss drugs like Ozempic and Wegovy, saving the city $10.6 million. This move addresses skyrocketing health costs that threatened 22.6% premium hikes. City workers must now get approval for coverage on these popular obesity treatments.
5 min read
Why Ozempic & GLP-1s Cost More in the US: A Guide
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
4 min read
Elderly Americans Abandon Weight-Loss Medications in Droves
Senior citizens in the U.S. often discontinue highly effective weight-loss medications such as GLP-1 drugs shortly after starting them, resulting in regained pounds and diminished health advantages. Side effects, high expenses, and inadequate insurance coverage frequently play key roles in this trend. Experts advocate for better coverage and ongoing research to address these challenges for older populations.
5 min read
Healthcare Costs in 2026: Some Will Pay More, Others Less
The healthcare landscape will undergo significant changes in 2026. Negotiated Medicare drug prices offer relief to some, but the expiration of Affordable Care Act tax credits and Medicaid uncertainties will increase costs for others.
6 min read
Two Emerging Developments Could Aid Future Lawsuits Demanding GLP-1 Coverage
Coverage remains a major hurdle for patients seeking GLP-1 medications for obesity, with Medicare and many private insurers not including them. However, two recent events could change the legal landscape: reduced medication costs and the WHO's classification of obesity as a chronic condition.
4 min read
GLP-1 Medications: A Century-Long History Influences Current Discussions
The ongoing discussion regarding insurer coverage for GLP-1 medications such as Ozempic and Wegovy has reignited a familiar debate concerning the origins of illness. Some argue these weight-loss drugs are shortcuts, while others emphasize the impact of socioeconomic factors on body weight.
1 min read
Mounjaro by Eli Lilly Approved for China's State Insurance Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
2 min read
WeightWatchers to Provide Novo Nordisk's Oral Wegovy Pending Approval Next Year | PharmExec
WeightWatchers intends to offer Novo Nordisk's oral Wegovy upon potential FDA approval. This strategic move occurs amidst a competitive weight-loss drug market, aiming to provide a convenient alternative to injections. The FDA is also expediting GLP-1 treatments to improve access.
3 min read